



(12) **United States Patent**
Zhu et al.

(10) **Patent No.:** **US 11,376,317 B2**
(45) **Date of Patent:** **Jul. 5, 2022**

(54) **FCRN-TARGETED MUCOSAL VACCINATION AGAINST RSV**
(71) Applicant: **University Of Maryland**, College Park, MD (US)
(72) Inventors: **Xiaoping Zhu**, Clarksville, MD (US); **Weizhong Li**, College Park, MD (US)
(73) Assignee: **UNIVERSITY OF MARYLAND, COLLEGE PARK**, College Park, MD (US)
(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **16/117,915**
(22) Filed: **Aug. 30, 2018**

(65) **Prior Publication Data**
US 2019/0060440 A1 Feb. 28, 2019

Related U.S. Application Data
(60) Provisional application No. 62/552,041, filed on Aug. 30, 2017.

(51) **Int. Cl.**
A61K 39/12 (2006.01)
C07K 14/005 (2006.01)
C07K 16/00 (2006.01)
A61P 31/14 (2006.01)
A61K 39/00 (2006.01)
A61K 9/00 (2006.01)
C07K 14/00 (2006.01)

(52) **U.S. Cl.**
CPC *A61K 39/12* (2013.01); *A61P 31/14* (2018.01); *C07K 14/005* (2013.01); *C07K 16/00* (2013.01); *A61K 9/0043* (2013.01); *A61K 2039/55561* (2013.01); *A61K 2039/55572* (2013.01); *C07K 14/00* (2013.01); *C07K 2317/52* (2013.01); *C07K 2319/30* (2013.01); *C12N 2760/18522* (2013.01); *C12N 2760/18534* (2013.01); *C12N 2760/18571* (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**
U.S. PATENT DOCUMENTS

2013/0164286 A1 6/2013 Chou et al.
2015/0079121 A1 3/2015 Weiner et al.

FOREIGN PATENT DOCUMENTS

WO PCT/US2018/055896 10/2018
WO WO-2019/046864 A1 3/2019

OTHER PUBLICATIONS

McLellan et al., Science vol. 342, p. 592-598, and Supplementary Materials (Year: 2013) (article and supp) 2 pdfs.*
Murphy et al. Virus Research vol. 32, pp. 13-26 (Year: 1994).*

Kang et al. Immunology Letters vol. 180, pp. 34-42 (Year: 2017).*
Lu et al., J Virology vol. 85, pp. 10542-10553 (Year: 2011).*
McLellan et al., Science vol. 342, p. 592-598, and Supplementary Materials (article and supp) 2 pdfs (Year: 2013).*
Shan et al. Communications Biology 1 (2021) 4:1048 | https://doi.org/10.1038/s42003-021-02565-5 | nature.com/commsbio (Year: 2021).*
Allie SR, Randall TD. Pulmonary immunity to viruses. Clin Sci (Lond). Jun. 30, 2017;131(14):1737-1762.
Berneman A, Belec L, Fischetti VA, Bouvet JP. 1998. The specificity patterns of human immunoglobulin G antibodies in serum differ from those in autologous secretions. Infect Immun. 66:4163-4168.
Boukhalova MS, Blanco JC. 2013. The cotton rat Sigmodon hispidus model of respiratory syncytial virus infection. Curr Top Microbiol Immunol. 372:347-58.
Castilow EM, Varga SM. 2008. Overcoming T cell-mediated immunopathology to achieve safe RSV vaccination. Future Virol. 3:445-454.
Cullen LM, Blanco JC, Morrison TG. 2015. Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. J Transl Med. 13:350.
Garg R, Latimer L, Simko E, Gerds V, Potter A, van den Hurk Sv. Induction of mucosal immunity and protection by intranasal immunization with a respiratory syncytial virus subunit vaccine formulation. J Gen Virol. Feb. 2014;95(Pt 2):301-6.
Garg R, Theaker M, Martinez EC, van Drunen Littel-van den Hurk S. A single intranasal immunization with a subunit vaccine formulation induces higher mucosal IgA production than live respiratory syncytial virus. Virology. Dec. 2016;499:288-297.
Gebriel A, Alsaadi M, Acevedo R, Mullen AB, Ferro VA. 2012. Optimizing efficacy of mucosal vaccines. Expert Rev Vaccines. 11:1139-55.
Graham BS, Modjarrad K, McLellan JS. 2015. Novel antigens for RSV vaccines. Curr Opin Immunol. 35:30-8.

(Continued)

Primary Examiner — Shanon A. Foley
Assistant Examiner — Myron G Hill
(74) *Attorney, Agent, or Firm* — Ballard Spahr LLP

(57) **ABSTRACT**

Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); a modified pre-fusion respiratory syncytia virus (RSV) F protein; and a trimerization domain. Disclosed are nucleic acid sequences capable of encoding peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a neonatal receptor (FcRn); a modified pre-fusion respiratory syncytia virus (RSV) F protein; and a trimerization domain. Also disclosed are methods for eliciting a protective immune response against RSV comprising administering to a subject an effective amount of a composition comprising a monomeric Fc fragment of an immunoglobulin recognized by FcRn; a modified pre-fusion RSV F protein; and a trimerization domain, wherein the administering is to a mucosal epithelium.

23 Claims, 4 Drawing Sheets

Specification includes a Sequence Listing.